Filana Therapeutics, Inc. Common Stock

Day range

$0.60 – $0.64

Open

$0.63

Prev close

$0.64

Volume

296.74K

Market cap

$30.7M

Shares out

48.31M

P/E

—

P/S

—

P/B

0.49

P/FCF

—

ROE

-66.5%

ROA

-40.7%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Material litigationOct 20, 2026

  Following the Company's successful appeal, further proceedings regarding class certification will proceed on remand in the Texas District Court pursuant to the Fifth Circuit's order. The Fifth Circuit concluded that the Texas District Court misapplied the applicable legal standard in certifying the class.

• Regulatory decisionSep 22, 2026

  “On September 22, 2026, the Company announced that the U.S. Food and Drug Administration has lifted the full clinical hold on the Company's investigational new drug (IND) application to initiate a planned Phase 2a proof-of-concept study for simufilam in tuberous sclerosis complex ("TSC")-related epilepsy.”

• Listing deficiency noticeSep 18, 2026

  On September 17, 2026, Filana Therapeutics, Inc. received written notice from Nasdaq indicating that the bid price for the Company's common stock, for the last thirty (30) consecutive business days, had closed below the minimum $1.00 per share and, as a result, the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2).

• Director departureApr 28, 2026

  On April 22, 2026, Michael O'Donnell notified the Board of Directors (the "Board") of Filana Therapeutics, Inc. (the "Company") of his decision to resign from the Board, effective at the conclusion of Company's 2026 annual meeting of stockholders. Mr. O'Donnell's resignation was not the result of any disagreement with the Company, management, or the Board on any matter relating to the Company's operations, policies, or practices.

Days to cover

1.0

Short interest

5.89M

Avg volume

9.67M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
  neutralGlobeNewswire Inc.· Oct 9, 2026